Skip to content

The effects of synbiotic supplementation on anti inflammatory index in lymphedema after breast cancer treatment

The effect of synbiotic supplementation on the serum concentration of anti-inflammatory factors and adiponectin in the survivors of Breast Cancer with Lymphedema

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017092023861N6
Enrollment
88
Registered
2017-09-26
Start date
2017-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema.

Interventions

Sponsors

Vice chancellor for research, Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with unilateral Breast Cancer Related Lymphedema; breast cancer lymphedema in STAGE = 2; age range of 18-60 years; BMI between 25 and 35; At least one month has passed since the last treatment such as radiotherapy; willingness to participate in the study Non-inclusion criteria: use of multi-vitamin minerals and omega-3 supplements up to 1 month before the study began; acute and chronic infection; history of autoimmune diseases such as rheumatoid arthritis; Inflammatory diseases such as heart failure, pulmonary, kidney and diabetes; taking supplements of probiotics from 6 months before study; having a weight loss diet in Length 6 months before the study; Smoking and alcohol consumption; Lymphedema due to other cancers Exclusion criteria : Unwillingness of the patient to continue research collaboration; No subsequent referral; Cancer recurrence during the study; Failure to follow a weight loss diet; Consumption of food and supplements containing probiotics during the study; Incidence of edema-like diseases such as renal, cardiovascular and respiratory failure during the study period; Metastasis; Infectious diseases in Study length; Consumption of less than 56 capsules of 70 capsules at the end of the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
IL-10. Timepoint: Before and after the intervention. Method of measurement: ELISA.

Secondary

MeasureTime frame
TGF-ß. Timepoint: Before and after the intervention. Method of measurement: ELISA.;VEGF. Timepoint: Before and after the intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before and after the intervention. Method of measurement: ELISA.;BMI. Timepoint: Before and after the intervention. Method of measurement: Weight ratio (kg) to squared height (m).;Skin fold thickness. Timepoint: Before and after the intervention. Method of measurement: caliper.;Waist. Timepoint: Before and after the intervention. Method of measurement: Meter (cm).;Waist to hip ratio. Timepoint: Before and after the intervention. Method of measurement: Calculate.;Nutrition status. Timepoint: Before and after the intervention. Method of measurement: Measurement of energy and nutrients intake using a 24-hour dietary recall questionnaire and anthropometric indices using scales and measurements.;Volume of lymphedema. Timepoint: Before and after the intervention. Method of measurement: water tank technique.;Physical activity. Timepoint: Before and after the intervention. Method of measurement: IPAQ questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Zarrati

Iran University of Medical Sciences, School of Public Health

zarrati.m@iums.ac.ir+98 21 8670 4814

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026